Teva R&D chief: Results in previous Laquinimod Phase III trials support its clinical utility as a unique multiple sclerosis treatment.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) and Active Biotech AB (OMX: ACTI) will launch a third Phase III clinical trial of Laquinimod, their once-daily oral treatment for the treatment of relapsing remitting multiple sclerosis, despite the failure of the previous trial. The trial will be held on the basis of an agreement on protocols with the US Food and Drug Administration (FDA).
The Concerto third Phase III laquinimod trial will evaluate two doses of the drug in 1,800 patients for up to 24 months. The primary endpoint will be confirmed disability progression as measured by the Expanded Disability Status Scale (EDSS).
Teva president Global R&D and chief scientific officer Dr. Michael Hayden said, "The results achieved in the previous Phase III trials of Laquinimod support the clinical utility of this compound as a unique treatment option for multiple sclerosis. We are encouraged by the FDA's agreement on the trial design and planned analysis, and look forward to further developing Laquinimod as a potential treatment option for multiple sclerosis patients."
Published by Globes [online], Israel business news - www.globes-online.com - on August 8, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012